Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction

PHASE4RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

November 30, 2025

Conditions
Heart Failure
Interventions
DRUG

Sacubitril-valsartan

level 1-24 / 26mg 2 times a day, level 2-49 / 51mg 2 times a day, level 3-97 / 103mg 2 times aday

DRUG

Enalapril

level 1-2.5 mg twice a day, level 2-5 mg twice a day, level 3-10 mg twice a day

DRUG

placebo

placebo matching for 24 / 26mg, 49 / 51mg, 97 / 103mg 2 of sacubitril/valsartan

DRUG

Placebo

placebo matching for 2.5 mg, 5 mg, 10 mg of enalapril

Trial Locations (5)

15-276

NOT_YET_RECRUITING

Medical University of Bialystok Clinical Hospital, Bialystok

80-952

NOT_YET_RECRUITING

University Clinical Centre in Gdańsk, Gdansk

45-401

NOT_YET_RECRUITING

University Clinical Hospital in Opole, Opole

61-848

RECRUITING

University Hospital in Poznan, Poznan

41-800

NOT_YET_RECRUITING

Specialist Hospital in Zabrze, Zabrze

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

collaborator

Medical University of Bialystok

OTHER

collaborator

University of Opole

OTHER

collaborator

Medical University of Gdansk

OTHER

collaborator

Medical University of Silesia

OTHER

lead

Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań

OTHER

NCT05487261 - Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction | Biotech Hunter | Biotech Hunter